Q2 EPS Estimate for Voyager Therapeutics Lowered by Analyst

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - HC Wainwright cut their Q2 2025 earnings estimates for Voyager Therapeutics in a research report issued on Wednesday, May 7th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.36) per share for the quarter, down from their prior forecast of ($0.22). HC Wainwright has a "Buy" rating and a $30.00 price objective on the stock. The consensus estimate for Voyager Therapeutics' current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Voyager Therapeutics' Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.58) EPS, Q1 2026 earnings at ($0.26) EPS, Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.27) EPS, Q4 2026 earnings at ($0.25) EPS, FY2028 earnings at ($1.46) EPS and FY2029 earnings at ($1.39) EPS.

VYGR has been the subject of a number of other reports. Wells Fargo & Company set a $10.00 price objective on shares of Voyager Therapeutics and gave the stock an "overweight" rating in a research note on Wednesday, March 12th. Canaccord Genuity Group reduced their price objective on shares of Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating for the company in a research note on Thursday, March 13th. Cantor Fitzgerald restated an "overweight" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Finally, Wedbush restated an "outperform" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $13.97.

Voyager Therapeutics Stock Performance

Shares of Voyager Therapeutics stock traded down $0.09 on Monday, reaching $3.19. The stock had a trading volume of 284,151 shares, compared to its average volume of 446,261. The business's 50-day moving average price is $3.49 and its two-hundred day moving average price is $4.88. Voyager Therapeutics has a fifty-two week low of $2.75 and a fifty-two week high of $9.55. The stock has a market cap of $176.52 million, a P/E ratio of 4.49 and a beta of 0.95.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.18). Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The firm had revenue of $6.47 million during the quarter, compared to analyst estimates of $13.55 million.

Institutional Investors Weigh In On Voyager Therapeutics

A number of hedge funds have recently added to or reduced their stakes in VYGR. Barclays PLC grew its holdings in Voyager Therapeutics by 55.8% during the 3rd quarter. Barclays PLC now owns 104,462 shares of the company's stock worth $612,000 after acquiring an additional 37,398 shares during the last quarter. SG Americas Securities LLC grew its holdings in Voyager Therapeutics by 86.7% during the 4th quarter. SG Americas Securities LLC now owns 23,044 shares of the company's stock worth $131,000 after acquiring an additional 10,704 shares during the last quarter. Empowered Funds LLC grew its holdings in Voyager Therapeutics by 5.3% during the 4th quarter. Empowered Funds LLC now owns 47,206 shares of the company's stock worth $268,000 after acquiring an additional 2,397 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Voyager Therapeutics by 23.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company's stock worth $223,000 after acquiring an additional 7,573 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in shares of Voyager Therapeutics by 3.4% in the 4th quarter. Rhumbline Advisers now owns 71,497 shares of the company's stock valued at $405,000 after purchasing an additional 2,354 shares during the last quarter. Institutional investors own 48.03% of the company's stock.

Insider Transactions at Voyager Therapeutics

In other news, CEO Alfred Sandrock sold 10,885 shares of the company's stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total value of $37,335.55. Following the sale, the chief executive officer now owns 430,931 shares of the company's stock, valued at approximately $1,478,093.33. This represents a 2.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 6.39% of the stock is owned by insiders.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.